在儿童多发性硬化症治疗中使用ocrelizumab的有效性和安全性
Ahmad Altelly1, Azza Mahmoud2, Victoria Mifsud2
1College of Medicine, University of Sharjah, Sharjah, United Arab Emirates.
Multiple sclerosis and related disorders
|August 23, 2025
概括
通过显著减少复发和维持残疾,ocrelizumab对儿童多发性硬化症 (MS) 是有前途的. 需要进一步的研究来确认在年轻患者中长期的安全性和有效性.
科学领域:
- 神经学
- 免疫学
- 儿童医学
背景情况:
- 对于儿童多发性硬化症 (POMS) 的抗CD20单克隆抗体ocrelizumab的数据有限.
- 这项研究针对阿联POMS患者的ocrelizumab的安全性和有效性.
研究的目的:
- 评估多发性硬化症诊断的儿科患者的ocrelizumab的安全性和疗效.
- 评估用ocrelizumab治疗的POMS患者的复发率,残疾进展 (EDSS),MRI发现和不良事件.
主要方法:
- 追溯队列研究分析了29名POMS患者的电子病历,这些患者在18岁之前接受了ocrelizumab治疗.
- 数据包括人口统计,病史,先前的治疗,复发率,MRI,IgG水平和EDSS得分.
主要成果:
- 在复发性复发性多发性硬化症患者中,ocrelizumab治疗导致年复发率 (ARR) 降低97%.
- 扩大残疾状况评分 (EDSS) 保持稳定;报告了轻微的输液反应和感染.
- 免疫球蛋白G (IgG) 水平稳定,治疗期间没有新的MRI病变或复发.
结论:
- 在POMS患者中,ocrelizumab表现出良好的短期耐受性和有效性,显著减少了复发.
- 稳定的残疾和可管理的不良事件表明潜在的益处,但需要更大规模的前性研究来进行长期验证.
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
267
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
267
01:22Dose-Response Relationship: Potency and Efficacy
5.2K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
5.2K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
231
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
231
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
202
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
202
01:11Clinical Trials: Overview
3.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.4K
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K